var data={"title":"Protamine sulfate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Protamine sulfate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6865?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=protamine-sulfate-drug-information\" class=\"drug drug_general\">see &quot;Protamine sulfate: Drug information&quot;</a> and <a href=\"topic.htm?path=protamine-sulfate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Protamine sulfate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7255805\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity reactions: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Protamine sulfate can cause severe hypotension, cardiovascular collapse, noncardiogenic pulmonary edema, catastrophic pulmonary vasoconstriction, and pulmonary hypertension. Risk factors include high dose or overdose, rapid administration, repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). Allergy to fish, previous vasectomy, and severe left ventricular dysfunction and abnormal preoperative pulmonary hemodynamics also may be risk factors. In patients with any of these risk factors, the risk to benefit of administration of protamine sulfate should be carefully considered. Vasopressors and resuscitation equipment should be immediately available in case of a severe reaction to protamine. Protamine sulfate should not be given when bleeding occurs without prior heparin use.  </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061565\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Heparin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12675557\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heparin or enoxaparin neutralization:</b> Limited data available: IV: Protamine dosage is determined by the most recent dosage of heparin or low molecular weight heparin (LMWH); 1 mg of protamine sulfate neutralizes ~100 units of heparin or 1 mg of enoxaparin; maximum protamine dose: 50 mg/dose. Dosing extrapolated from experience in adult patients (ACCP [Mongale 2012]; Lovenox prescribing information 2013; Park 2014). <b>Note:</b> When heparin is given as a continuous IV infusion, only heparin given in the preceding several hours (eg, 2 hours) should be considered when administering protamine (ACCP [Monagle 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heparin overdosage following intravenous administration:</b> Limited data available (ACCP [Monagle 2012]):  IV: Since blood heparin concentrations decrease rapidly <b>after</b> heparin administration, adjust the protamine dosage depending upon the duration of time since heparin administration as follows (see table): </p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\"> Time Since Last Heparin Dose</p>\n            <p style=\"text-indent:0em;\">(min)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose of Protamine (mg) to Neutralize</p>\n            <p style=\"text-indent:0em;\">100 units of Heparin</p></th></tr></thead>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5 to 0.75</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 to 120</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.375 to 0.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;120</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.25 to 0.375</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Enoxaparin overdosage:</b> Limited data available; dosing based on experience in adult patients (ACCP [Monagle 2012]; Park, 2014): <b>Note:</b> Anti-Xa activity is never completely neutralized (maximum: ~60% to 75%). Excessive protamine doses may worsen bleeding potential.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Enoxaparin last administered in &le;8 hours:</i> IV: Dose of protamine sulfate should equal the dose of enoxaparin administered; therefore, 1 mg protamine neutralizes 1 mg enoxaparin (Lovenox prescribing information 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Enoxaparin last administered in &gt; 8 hours or if it has been determined that second dose of protamine is required (eg, if aPTT measured 2 to 4 hours after the first dose remains prolonged or if bleeding continues):</i> IV: 0.5 mg protamine per 1 mg enoxaparin  (Lovenox prescribing information 2013). One report of a 10-fold enoxaparin overdose in a neonate (40 mg dose of enoxaparin administered) described using smaller protamine aliquots (10 mg) of the total protamine dose every 2 to 3 hours until the anti-Xa level was &lt; 2 units/mL to avoid potential protamine toxicity from administration of a large single dose (Wiernikowski 2007).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061560\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=protamine-sulfate-drug-information\" class=\"drug drug_general\">see &quot;Protamine sulfate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <b>Heparin or enoxaparin neutralization:</b> Limited data available: Infants, Children, and Adolescents: IV: Protamine dosage is determined by the most recent dosage of heparin or low molecular weight heparin (LMWH); 1 mg of protamine sulfate neutralizes ~100 units of heparin or 1 mg of enoxaparin; maximum protamine dose: 50 mg/dose. Dosing extrapolated from experience in adult patients (ACCP [Mongale 2012]; Lovenox prescribing information 2013; Park 2014). <b>Note:</b> When heparin is given as a continuous IV infusion, only heparin given in the preceding several hours (eg, 2 hours) should be considered when administering protamine (ACCP [Monagle 2012]). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <b>Heparin overdosage following intravenous administration:</b> Limited data available (ACCP [Monagle 2012): Infants, Children, and Adolescents: Since blood heparin concentrations decrease rapidly <b>after</b> heparin administration, adjust the protamine dosage depending upon the duration of time since heparin administration as follows (see table): </p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\"> Time Since Last Heparin Dose</p>\n            <p style=\"text-indent:0em;\">(min)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose of Protamine (mg) to Neutralize</p>\n            <p style=\"text-indent:0em;\">100 units of Heparin</p></th></tr></thead>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5 to 0.75</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 to 120</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.375 to 0.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;120</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.25 to 0.375</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Heparin overdosage following subcutaneous administration</b>: Limited data available: Infants, Children, and Adolescents: 1 to 1.5 mg protamine per 100 units heparin; this may be done by administering a portion of the protamine dose (eg, 25 to 50 mg) slowly IV followed by the remaining portion as a continuous infusion over 8 to 16 hours (the expected absorption time of the SubQ heparin dose) (Caravati 2004); dosing extrapolated from experience in adult patients (ACCP [Monagle 2012]; Park 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>LMWH overdosage (enoxaparin, dalteparin):</b> Limited data available: Infants, Children, and Adolescents: <b>Note:</b> Anti-Xa activity is never completely neutralized (maximum: ~60% to 75%). Excessive protamine doses may worsen bleeding potential; dosing extrapolated from experience in adult patients (ACCP [Monagle 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Enoxaparin: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Enoxaparin dose administered &le;8 hours:</i> IV: Dose of protamine should equal the dose of enoxaparin administered; therefore, 1 mg protamine sulfate neutralizes per 1 mg of enoxaparin (Lovenox prescribing information 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Enoxaparin administered &gt;8 hours prior or if it has been determined that a second dose of protamine is required (eg, if aPTT measured 2 to 4 hours after the first dose remains prolonged or if bleeding continues):</i> IV: 0.5 mg protamine sulfate for every 1 mg enoxaparin (Lovenox prescribing information 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Dalteparin: IV: 1 mg protamine for each 100 anti-Xa units of dalteparin; if PTT prolonged 2 to 4 hours after first dose (or if bleeding continues), consider additional dose of 0.5 mg for each 100 anti-Xa units of dalteparin (Fragmin prescribing information 2010).   </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heparin neutralization:</b> IV: Protamine dosage is determined by the dosage of heparin; 1 mg of protamine neutralizes ~100 units of heparin; maximum dose: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> When heparin is given as a continuous IV infusion, only heparin given in the preceding several hours should be considered when administering protamine. For example, a patient receiving heparin at 1,250 units/hour will require ~30 mg of protamine for reversal of heparin given in the last 2 to 2.5 hours (Garcia 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heparin overdosage, following intravenous administration:</b> IV: Since blood heparin concentrations decrease rapidly after administration, adjust the protamine dosage depending upon the duration of time since heparin administration as follows (see table):</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\"> Time Elapsed</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose of Protamine (mg) to Neutralize</p>\n            <p style=\"text-indent:0em;\">100 units of Heparin</p></th></tr></thead>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Immediate</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 1.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 60 minutes</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5 to 0.75</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.25 to 0.375</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heparin overdosage, following SubQ injection:</b> IV: 1 to 1.5 mg protamine per 100 units heparin; this may be done by a portion of the dose (eg, 25 to 50 mg) given slowly IV followed by the remaining portion as a continuous infusion over 8 to 16 hours (the expected absorption time of the SubQ heparin dose) (Caravati 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>LMWH overdose:</b> IV: <b>Note:</b> Anti-Xa activity is never completely neutralized (maximum: ~60% to 75%). Excessive protamine doses may worsen bleeding potential.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Enoxaparin (Lovenox prescribing information 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Enoxaparin administered in &le;8 hours: Dose of protamine should equal the dose of enoxaparin administered. Therefore, 1 mg of protamine sulfate neutralizes 1 mg of enoxaparin.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Enoxaparin administered in &gt;8 hours or if it has been determined that a second dose of protamine is required (eg, if aPTT measured 2 to 4 hours after the first dose remains prolonged or if bleeding continues): 0.5 mg of protamine sulfate for every 1 mg of enoxaparin administered</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dalteparin (Fragmin prescribing information 2010): 1 mg protamine for each 100 anti-Xa units of dalteparin; if PTT prolonged 2 to 4 hours after first dose (or if bleeding continues), consider additional dose of 0.5 mg for each 100 anti-Xa units of dalteparin  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustment provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215125\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (5 mL, 25 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sulfate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (5 mL, 25 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215111\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061568\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: IV: Administer undiluted slow IVP at a rate not to exceed 5 mg/minute (50 mg in any 10-minute period); rapid IV infusion causes hypotension </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215136\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Do not freeze. Diluted solutions should not be stored.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061567\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of heparin overdosage (FDA approved in adults); has also been used to neutralize heparin during surgery or dialysis procedures and as antidote for low molecular weight heparin (LMWH) overdose or reversal </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215175\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Protamine may be confused with ProAmatine, Protonix, Protopam</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215172\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, flushing, hypotension, sudden decrease of blood pressure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Lassitude</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, pulmonary hypertension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215131\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to protamine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215115\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heparin rebound: Heparin rebound associated with anticoagulation and bleeding has been reported to occur occasionally; symptoms typically occur 8-9 hours after protamine administration, but may occur as long as 18 hours later.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: May cause hypersensitivity reaction in patients (have epinephrine 1 mg/mL  and resuscitation equipment available). <b>[US Boxed Warning]: Hypotension, cardiovascular collapse, noncardiogenic pulmonary edema, pulmonary vasoconstriction, and pulmonary hypertension may occur. Risk factors for such events include use of high doses or overdose, repeated doses, previous protamine administration (including protamine-containing drugs), fish allergy, vasectomy, severe left ventricular dysfunction, and abnormal preoperative pulmonary hemodynamics.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infusion reactions: Too rapid administration can cause severe hypotensive and anaphylactoid-like reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiac surgery patients: May be ineffective in some patients following cardiac surgery despite adequate doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299956\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222615\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12746&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215121\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13801118\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003). Protamine sulfate may be used during delivery to reduce the risk of bleeding following maternal use of heparin or low molecular weight heparin (LMWH) (Bates,  2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061564\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Coagulation tests, APTT or ACT, cardiac monitor, and blood pressure monitor required during administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215114\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Protamine, a highly alkaline protein molecule with a large positive charge, has weak anticoagulant activity when administered alone. When protamine is given in the presence of heparin (strongly acidic and negatively charged), a stable salt is formed and the anticoagulant activity of both drugs is nullified (Pai 2012). In the presence of LMWH, protamine incompletely reverses the antifactor Xa activity of LMWH (Makris 2000; Massonnet-Castel 1986; Racanelli 1985).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215130\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IV: Heparin neutralization: ~5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~7 minutes </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323746\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Protamine Sulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (5 mL): $11.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038788\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Denpru (AR);</li>\n      <li>Prosulf (GB);</li>\n      <li>Protamina (ES);</li>\n      <li>Protamina solfato (IT);</li>\n      <li>Protamine Choay (FR);</li>\n      <li>Protamine Sulfate Injection (AU);</li>\n      <li>Protamine Sulphate (GB);</li>\n      <li>Protamine Sulphate Injection BP (AU);</li>\n      <li>Protamini Sulfas (FI);</li>\n      <li>Protaminsulfat (NO);</li>\n      <li>Protaminsulfat Novo (AT);</li>\n      <li>Protaminsulfat &rdquo;Leo&rdquo; (DE, DK);</li>\n      <li>Protaminum Sulfuricum (PL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bates SM, Greer IA, Middeldorp S, et al. &ldquo;VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):e691-736.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-pediatric-drug-information/abstract-text/22315276/pubmed\" target=\"_blank\" id=\"22315276\">22315276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caravati EM. Protamine sulfate. <i>Medical Toxicology</i>. 3rd ed. Dart RC, ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004;243-244.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fragmin (protamine) [prescribing information]. New York, NY: Pfizer Inc; October 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia DA, Baglin TP, Weitz JI, Samama MM; American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 Suppl):e24S-43S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-pediatric-drug-information/abstract-text/22315264 /pubmed\" target=\"_blank\" id=\"22315264 \">22315264 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lovenox (Protamine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; April 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moganasundram S, Hunt BJ, Sykes K, et al, &quot;The Relationship Among Thromboelastography, Hemostatic Variables, and Bleeding After Cardiopulmonary Bypass Surgery in Children,&quot; <i>Anesth Analg</i>, 2010, 110(4):995-1002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-pediatric-drug-information/abstract-text/20142345/pubmed\" target=\"_blank\" id=\"20142345\">20142345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Chan A, Goldenberg, N, et al. <i>Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</i> . 9th ed.  <i>Chest</i>. 2012, 141(2 Suppl):737-801.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Protamine (prescribing information). Lake Zurich, IL: Fresenius Kabi USA, LLC; November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiernikowski JT, Chan A, and Lo G, &quot;Reversal of Anti-Thrombin Activity Using Protamine Sulfate. Experience in a Neonate With a 10-fold Overdose of Enoxaparin,&quot; <i>Thromb Res</i>, 2007, 120(2):303-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-pediatric-drug-information/abstract-text/17079003/pubmed\" target=\"_blank\" id=\"17079003\">17079003</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12746 Version 81.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F7255805\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061565\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12675557\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061560\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F215125\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F215111\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061568\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F215136\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061567\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F215175\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F215172\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F215131\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F215115\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299956\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222615\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F215121\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13801118\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1061564\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F215114\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F215130\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323746\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038788\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12746|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=protamine-sulfate-drug-information\" class=\"drug drug_general\">Protamine sulfate: Drug information</a></li><li><a href=\"topic.htm?path=protamine-sulfate-patient-drug-information\" class=\"drug drug_patient\">Protamine sulfate: Patient drug information</a></li></ul></div></div>","javascript":null}